Lenvatinib + Lenvatinib matching placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Thyroid Cancer

Conditions

Thyroid Cancer

Trial Timeline

Jun 8, 2017 → Sep 10, 2020

NCT ID

NCT02702388

About Lenvatinib + Lenvatinib matching placebo

Lenvatinib + Lenvatinib matching placebo is a phase 2 stage product being developed by Eisai for Thyroid Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02702388. Target conditions include Thyroid Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Thyroid Cancer were approved

Approved (20) Terminated (4) Active (0)

✅LenvatinibEisaiApproved

✅Cinacalcet HClKyowa KirinApproved

✅Growth hormone + Growth hormone treatment and pubertyEli LillyApproved

✅Paricalcitol + CalcifediolAbbVieApproved

✅Paricalcitol + Darbepoetin alfaAbbVieApproved

✅Alendronate 70mg weeklyMerckApproved

✅AMG 073AmgenApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02702388	Phase 2	Completed	Jun 8, 2017	Sep 10, 2020	Thyroid Cancer

Competing Products

20 competing products in Thyroid Cancer

See all competitors

Product	Company	Stage	Hype Score
MBX 2109	MBX Biosciences	Phase 2	29
400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection	MBX Biosciences	Phase 2	33
PCO371 + Placebo	Chugai Pharmaceutical	Phase 1	21
CS-7017 + Paclitaxel	Daiichi Sankyo	Phase 1/2	24
efatutazone + paclitaxel	Daiichi Sankyo	Phase 2	35
ASP7991 + Cinacalcet + Placebo	Astellas Pharma	Phase 2	35
Lenvatinib	Eisai	Pre-clinical	26
Lenvatinib	Eisai	Pre-clinical	26
Lenvatinib + Placebo + Lenvatinib	Eisai	Phase 3	40
Irofulven + capecitabine	Eisai	Phase 2	35
Lenvatinib + Placebo	Eisai	Phase 3	40
Lenvatinib	Eisai	Approved	43
Lenvatinib	Eisai	Pre-clinical	26
Bexarotene	Eisai	Phase 1	29
Lenvatinib	Eisai	Phase 2	27
LENVATINIB	Eisai	Phase 2	39
E7080 capsule	Eisai	Phase 2	35
Lenvatinib (DTC Cohort) + Lenvatinib (MTC Cohort)	Eisai	Phase 2	35
Lenvatinib 24 mg	Eisai	Phase 2	27
KHK7580 + KRN1493	Kyowa Kirin	Phase 2/3	38